{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:14:07Z","timestamp":1787868847687,"version":"build-2784847793"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00520-019-05168-3","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T18:02:51Z","timestamp":1574186571000},"page":"3267-3278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3716-2559","authenticated-orcid":false,"given":"A.","family":"Rogiers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Leys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"De Cremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Awada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schembri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Theuns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"De Ridder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Neyns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,19]]},"reference":[{"key":"5168_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejca.2016.07.007","volume":"65","author":"L Liu","year":"2016","unstructured":"Liu L, O\u2019Donnell P, Sullivan R, Katalinic A, Moser L, de Boer A et al (2016) Cancer in Europe: death sentence or life sentence? Eur J Cancer 65:150\u2013155","journal-title":"Eur J Cancer"},{"key":"5168_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00520-017-3880-8","volume":"26","author":"MA Annunziata","year":"2018","unstructured":"Annunziata MA, Muzzatti B, Flaiban C, Gipponi K, Carnaghi C, Tralongo P, Caruso M, Cavina R, Tirelli U (2018) Long-term quality of life profile in oncology: a comparison between cancer survivors and the general population. Support Care Cancer 26:651\u2013656","journal-title":"Support Care Cancer"},{"key":"5168_CR3","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1007\/s00520-018-4270-6","volume":"26","author":"S Paltrinieri","year":"2018","unstructured":"Paltrinieri S, Fugazzaro S, Bertozzi L, Bassi MC, Pellegrini M, Vicentini M, Mazzini E, Costi S (2018) Return to work in European Cancer survivors: a systematic review. Support Care Cancer 26:2983\u20132994","journal-title":"Support Care Cancer"},{"key":"5168_CR4","doi-asserted-by":"crossref","unstructured":"Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejbergs L et al (2019) Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol","DOI":"10.1093\/annonc\/mdz110"},{"key":"5168_CR5","doi-asserted-by":"publisher","first-page":"5269062","DOI":"10.1155\/2019\/5269062","volume":"2019","author":"A Rogiers","year":"2019","unstructured":"Rogiers A, Boekhout A, Schwarze JK, Awada G, Blank CU, Neyns B (2019) Long-term survival, quality of life, and psychosocial outcomes in advanced melanoma patients treated with immune checkpoint inhibitors. J Oncol 2019:5269062","journal-title":"J Oncol"},{"key":"5168_CR6","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","volume":"36","author":"C Robert","year":"2018","unstructured":"Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS (2018) Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol 36:1668\u20131674","journal-title":"J Clin Oncol"},{"key":"5168_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejca.2016.07.018","volume":"67","author":"D Schadendorf","year":"2016","unstructured":"Schadendorf D, Dummer R, Hauschild A, Robert C, Hamid O, Daud A, van den Eertwegh A, Cranmer L, O'Day S, Puzanov I, Schachter J, Blank C, Salama A, Loquai C, Mehnert JM, Hille D, Ebbinghaus S, Kang SP, Zhou W, Ribas A (2016) Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. Eur J Cancer 67:46\u201354","journal-title":"Eur J Cancer"},{"key":"5168_CR8","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1056\/NEJMp1901103","volume":"380","author":"T Langbaum","year":"2019","unstructured":"Langbaum T, Smith TJ (2019) Time to study metastatic-cancer survivorship. N Engl J Med 380:1300\u20131302","journal-title":"N Engl J Med"},{"issue":"2","key":"5168_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00520-019-04818-w","volume":"28","author":"Aine O\u2019Reilly","year":"2019","unstructured":"O\u2019Reilly A, Hughes P, Mann J, Lai Z, Teh JJ, McLean E, et al. (2019) An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. Support Care Cancer https:\/\/doi.org\/10.1007\/s00520-019-04818-w","journal-title":"Supportive Care in Cancer"},{"key":"5168_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ejca.2016.10.008","volume":"69","author":"JF Hamel","year":"2016","unstructured":"Hamel JF, Pe M, Coens C, Martinelli F, Eggermont AM, Brandberg Y, Bottomley A (2016) A systematic review examining factors influencing health related quality of life among melanoma cancer survivors. Eur J Cancer 69:189\u2013198","journal-title":"Eur J Cancer"},{"key":"5168_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116440","volume":"10","author":"ME Beutel","year":"2015","unstructured":"Beutel ME, Fischbeck S, Binder H, Blettner M, Brahler E, Emrich K et al (2015) Depression, anxiety and quality of life in long-term survivors of malignant melanoma: a register-based cohort study. PLoS One 10:e0116440","journal-title":"PLoS One"},{"key":"5168_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/5269062","volume":"2019","author":"Anne Rogiers","year":"2019","unstructured":"Rogiers A, Boekhout A, Schwarze JK, Awada G, Blank CU, Neyns B (2019) Long-term survival, quality of life, and psychosocial outcomes in advanced melanoma patients treated with immune checkpoint inhibitors. J Oncol 1-17 https:\/\/doi.org\/10.1155\/2019\/5269062","journal-title":"Journal of Oncology"},{"issue":"5","key":"5168_CR13","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00520-018-4443-3","volume":"27","author":"David Levy","year":"2018","unstructured":"Levy D, Dhillon HM, Lomax A, Marthick M, McNeil C, Kao S, et al. (2018) Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy. Support Care Cancerhttps:\/\/doi.org\/10.1007\/s00520-018-4443-3","journal-title":"Supportive Care in Cancer"},{"key":"5168_CR14","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00262-014-1617-9","volume":"63","author":"JW Eng","year":"2014","unstructured":"Eng JW, Kokolus KM, Reed CB, Hylander BL, Ma WW, Repasky EA (2014) A nervous tumor microenvironment: the impact of adrenergic stress on cancer cells, immunosuppression, and immunotherapeutic response. Cancer Immunol Immunother 63:1115\u20131128","journal-title":"Cancer Immunol Immunother"},{"key":"5168_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pnpbp.2014.01.013","volume":"53","author":"JD Rosenblat","year":"2014","unstructured":"Rosenblat JD, Cha DS, Mansur RB, McIntyre RS (2014) Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuro-Psychopharmacol Biol Psychiatry 53:23\u201334","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"5168_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/1741-7015-11-200","volume":"11","author":"M Berk","year":"2013","unstructured":"Berk M, Williams LJ, Jacka FN, O\u2019Neil A, Pasco JA, Moylan S et al (2013) So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 11:200","journal-title":"BMC Med"},{"key":"5168_CR17","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1200\/JCO.2007.10.7805","volume":"26","author":"AH Miller","year":"2008","unstructured":"Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR (2008) Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 26:971\u2013982","journal-title":"J Clin Oncol"},{"key":"5168_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.psyneuen.2018.09.012","volume":"99","author":"AK Walker","year":"2019","unstructured":"Walker AK, Martelli D, Ziegler AI, Lambert GW, Phillips SE, Hill SJ, McAllen R, Sloan EK (2019) Circulating epinephrine is not required for chronic stress to enhance metastasis. Psychoneuroendocrinology. 99:191\u2013195","journal-title":"Psychoneuroendocrinology."},{"key":"5168_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361\u2013370","journal-title":"Acta Psychiatr Scand"},{"key":"5168_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1017\/S0033291796004382","volume":"27","author":"P Spinhoven","year":"1997","unstructured":"Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM (1997) A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med 27:363\u2013370","journal-title":"Psychol Med"},{"key":"5168_CR21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s12888-014-0354-0","volume":"14","author":"C Bocerean","year":"2014","unstructured":"Bocerean C, Dupret E (2014) A validation study of the Hospital Anxiety and Depression Scale (HADS) in a large sample of French employees. BMC Psychiatry 14:354","journal-title":"BMC Psychiatry"},{"key":"5168_CR22","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/j.1365-2354.2010.01217.x","volume":"20","author":"L Castelli","year":"2011","unstructured":"Castelli L, Binaschi L, Caldera P, Mussa A, Torta R (2011) Fast screening of depression in cancer patients: the effectiveness of the HADS. Eur J Cancer Care (Engl) 20:528\u2013533","journal-title":"Eur J Cancer Care (Engl)"},{"key":"5168_CR23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"5168_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139\u2013144","journal-title":"J Clin Oncol"},{"key":"5168_CR25","first-page":"24","volume-title":"EORTC Quality of life group translation procedure","author":"EORTC B","year":"2017","unstructured":"EORTC B (2017) EORTC Quality of life group translation procedure, fourth edn. EORTC, Brussels, p 24","edition":"fourth"},{"key":"5168_CR26","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","volume":"46","author":"LB Krupp","year":"1989","unstructured":"Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121\u20131123","journal-title":"Arch Neurol"},{"key":"5168_CR27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1023\/A:1008331230608","volume":"11","author":"P Stone","year":"2000","unstructured":"Stone P, Richards M, A\u2019Hern R, Hardy J (2000) A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 11:561\u2013567","journal-title":"Ann Oncol"},{"key":"5168_CR28","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.3109\/09638281003734458","volume":"32","author":"MB Rietberg","year":"2010","unstructured":"Rietberg MB, Van Wegen EE, Kwakkel G (2010) Measuring fatigue in patients with multiple sclerosis: reproducibility, responsiveness and concurrent validity of three Dutch self-report questionnaires. Disabil Rehabil 32:1870\u20131876","journal-title":"Disabil Rehabil"},{"key":"5168_CR29","first-page":"1139","volume":"158","author":"M Debouverie","year":"2002","unstructured":"Debouverie M, Pittion S, Guillemin F, Vespignani H (2002) Fatigue scales used in multiple sclerosis. Rev Neurol (Paris) 158:1139\u20131143","journal-title":"Rev Neurol (Paris)"},{"key":"5168_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11060-015-1971-2","volume":"126","author":"C Caine","year":"2016","unstructured":"Caine C, Deshmukh S, Gondi V, Mehta M, Tome W, Corn BW et al (2016) CogState computerized memory tests in patients with brain metastases: secondary endpoint results of NRG Oncology RTOG 0933. J Neuro-Oncol 126:327\u2013336","journal-title":"J Neuro-Oncol"},{"key":"5168_CR31","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00520-006-0037-6","volume":"14","author":"J Vardy","year":"2006","unstructured":"Vardy J, Wong K, Yi QL, Park A, Maruff P, Wagner L, Tannock IF (2006) Assessing cognitive function in cancer patients. Support Care Cancer 14:1111\u20131118","journal-title":"Support Care Cancer"},{"key":"5168_CR32","unstructured":"Cogstate L (2017) Cogstate pediatric and adult normative data. Copyright \u00a9 2017 CogState, Ltd. All rights reserved."},{"key":"5168_CR33","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3389\/fpsyg.2015.00704","volume":"6","author":"JA Cromer","year":"2015","unstructured":"Cromer JA, Schembri AJ, Harel BT, Maruff P (2015) The nature and rate of cognitive maturation from late childhood to adulthood. Front Psychol 6:704","journal-title":"Front Psychol"},{"key":"5168_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/0891988712447894","volume":"25","author":"D Hammers","year":"2012","unstructured":"Hammers D, Spurgeon E, Ryan K, Persad C, Barbas N, Heidebrink J, Darby D, Giordani B (2012) Validity of a brief computerized cognitive screening test in dementia. J Geriatr Psychiatry Neurol 25:89\u201399","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"5168_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020469","volume":"6","author":"T Yoshida","year":"2011","unstructured":"Yoshida T, Suga M, Arima K, Muranaka Y, Tanaka T, Eguchi S et al (2011) Criterion and construct validity of the CogState Schizophrenia Battery in Japanese patients with schizophrenia. PLoS One 6:e20469","journal-title":"PLoS One"},{"key":"5168_CR36","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1037\/0894-4105.10.1.120","volume":"10","author":"Ingraham","year":"1996","unstructured":"Ingraham (1996) An empirical approach to determining criteria for abnormality in test batteries with multiple measures. Neuropsychology 10:120\u2013124","journal-title":"Neuropsychology"},{"key":"5168_CR37","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S1470-2045(10)70294-1","volume":"12","author":"JS Wefel","year":"2011","unstructured":"Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12:703\u2013708","journal-title":"Lancet Oncol"},{"key":"5168_CR38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0165-1781(98)00038-9","volume":"79","author":"J Ventura","year":"1998","unstructured":"Ventura J, Liberman RP, Green MF, Shaner A, Mintz J (1998) Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I\/P). Psychiatry Res 79:163\u2013173","journal-title":"Psychiatry Res"},{"key":"5168_CR39","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3109\/0284186X.2013.879998","volume":"53","author":"A Hinz","year":"2014","unstructured":"Hinz A, Singer S, Brahler E (2014) European reference values for the quality of life questionnaire EORTC QLQ-C30: results of a German investigation and a summarizing analysis of six European general population normative studies. Acta Oncol 53:958\u2013965","journal-title":"Acta Oncol"},{"key":"5168_CR40","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1001\/archdermatol.2009.308","volume":"145","author":"NA Kasparian","year":"2009","unstructured":"Kasparian NA, McLoone JK, Butow PN (2009) Psychological responses and coping strategies among patients with malignant melanoma: a systematic review of the literature. Arch Dermatol 145:1415\u20131427","journal-title":"Arch Dermatol"},{"key":"5168_CR41","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1056\/NEJMra1612499","volume":"376","author":"A Shalev","year":"2017","unstructured":"Shalev A, Liberzon I, Marmar C (2017) Post-traumatic stress disorder. N Engl J Med 376:2459\u20132469","journal-title":"N Engl J Med"},{"key":"5168_CR42","doi-asserted-by":"crossref","unstructured":"Lai-Kwon J, Khoo C, Lo S, Milne D, Mohamed M, Raleigh J, et al. (2019) The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. J Cancer Surviv","DOI":"10.1007\/s11764-019-00770-0"},{"key":"5168_CR43","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1200\/JCO.2016.68.2278","volume":"34","author":"M Dieng","year":"2016","unstructured":"Dieng M, Butow PN, Costa DS, Morton RL, Menzies SW, Mireskandari S, Tesson S, Mann GJ, Cust AE, Kasparian NA (2016) Psychoeducational intervention to reduce fear of cancer recurrence in people at high risk of developing another primary melanoma: results of a randomized controlled trial. J Clin Oncol 34:4405\u20134414","journal-title":"J Clin Oncol"},{"issue":"5","key":"5168_CR44","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1093\/annonc\/mdz083","volume":"30","author":"F. Bartels","year":"2019","unstructured":"Bartels F, Stronisch T, Farmer K, Rentzsch K, Kiecker F, Finke C (2019) Neuronal autoantibodies associated with cognitive impairment in melanoma patients. Ann Oncol https:\/\/doi.org\/10.1093\/annonc\/mdz083","journal-title":"Annals of Oncology"},{"key":"5168_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-015860","volume":"7","author":"M Duncan","year":"2017","unstructured":"Duncan M, Moschopoulou E, Herrington E, Deane J, Roylance R, Jones L et al (2017) Review of systematic reviews of non-pharmacological interventions to improve quality of life in cancer survivors. BMJ Open 7:e015860","journal-title":"BMJ Open"},{"key":"5168_CR46","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1200\/JCO.2015.61.6672","volume":"33","author":"HM Conklin","year":"2015","unstructured":"Conklin HM, Ogg RJ, Ashford JM, Scoggins MA, Zou P, Clark KN, Martin-Elbahesh K, Hardy KK, Merchant TE, Jeha S, Huang L, Zhang H (2015) Computerized cognitive training for amelioration of cognitive late effects among childhood cancer survivors: a randomized controlled trial. J Clin Oncol 33:3894\u20133902","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-05168-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-05168-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-05168-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T04:27:55Z","timestamp":1605673675000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-05168-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,19]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["5168"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-05168-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,19]]},"assertion":[{"value":"28 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study ( Identifier: NCT02673970) on \u201cBiomarkers for the activity of immune checkpoint inhibitor therapy in patients with advanced melanoma\u201d, was approved by the Ethical Committee (EC) of the Universitair Ziekenhuis Brussel in 2014, and the sub-study in April 2016.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"AR has consulting and advisory role in the Bristol-Myers Squibb and Merck Sharp & Dome. GA received travel accommodations from the Merck Sharp & Dome and Pfizer, research grant from the Pfizer and Novartis. AS is a full-time employee of the Cogstate Ltd., the company that provided the computerized cognitive tests in this study. MD received research agreement from the Brainlab AG, and has consulting or advisory role in the Novalis Certification Expert. BN received honoraria from the Bristol-Myers Squibb, Merck Sharp & Dome, Novartis, and Roche, has consulting or advisory role in the Bristol-Myers Squibb, Merck Sharp & Dome, Novartis, Roche, Speakers\u2019 Bureau-Novartis, and received travel, accommodations, and expenses from the Amgen, Bristol-Myers Squibb, Merck Sharp & Dome, Novartis, and Roche.The other authors have no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}